BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
REVIEWER
Hisao Imai Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Japan REVIEW RETURNED 12-Feb-2018 GENERAL COMMENTS This article is well written. Post progression survival is important for lung cancer patients to control overall survival. Patients haboring BRAF V600E mutation is also important for PPS. This article suggests the importance of PPS for those patients.

Kari Chansky Cancer Research And Biostatistics, USA REVIEW RETURNED
18-Feb-2018
GENERAL COMMENTS
The presentation must include a tabulation of the patient characteristics within each comparison group (TTP<6mos vs >=6 months). Currently the tabulation is shown by treatment cohort, which is interesting but not helpful in evaluating the results of the analysis. It is impossible to evaluate the correctness of the conclusions without knowing whether there are imbalances. A very likely imbalance in the number of prior treatment regimens is particularly concerning. Multivariable analysis is helpful but does not completely eliminate doubts around imbalances, and the Kaplan Meier analyses are not adjusted for potential imbalances in these characteristics.
The text indicates that the data are from a non-randomized trial, but Figure 1 indicates that patients were randomized. Please clarify.
Additionally it is worth mentioning that if the trial is not finished and has not been reported, this paper seems to prematurely reveal some information about the outcomes In this study, the authors use data from patients enrolled in a phase II trial of dabrafenib alone and combined with trametinib to investigate the association between time to progression (TTP) and overall survival (OS) in advanced, BRAF V600E-positive non-small-cell lung cancer. The underlying question of whether "any improvement in TTP is offset by loss of survival time in the post-progression period", as stated by authors, is critical in my opinion, but the approach used by the authors is potentially biased. Essentially, comparing patients with a long (6 months or longer) and a short (<6 months) TTP is subject to guarantee-time bias, in the sense that the former patients are inherently "better" than the latter. In order to investigate the potential for guarantee-time bias, at least a landmark analysis should be conducted, perhaps using the 6-month point for which authors provide a rationale. Such analysis would classify patients into two groups (progression-free at 6 months vs those still alive but already having a progression at 6 months) and exclude patients dying before 6 months of follow-up. Authors should note, however, that other methods are available for this type of analysis.
Response: Thank you for your thoughtful comments on the research question and approach. We agree with your suggestion that landmark analyses will help to address the potential of guaranteetime bias and strengthen the paper. We first conducted a landmark analysis that excluded patients who died or were censored prior to 6 months after disease progression. The results have shown that the positive association between TTP and PPS holds in the 6-month landmark analysis (Supplementary Tables 6 & 7 , Supplementary Figure 3) . However, no statistical significance was observed due to small sample sizes (total N=59; 35 with TTP ≥ 6 months; 24 with TTP < 6 months). To further support our conclusion in the main analysis, we conducted another landmark analysis with larger sample sizes that excluded patients who died or were censored prior to 3 months after progression (total N=75; 35 with TTP ≥ 6 months; 40 with TTP < 6 months). The significant, positive association between TTP and PPS was observed in the 3-month landmark analysis (Supplementary  Tables 4 & 5 , Supplementary Figure 2) . A description of the results from the landmark analyses has been added to the Methods and Results sections. These landmark analyses further support the conclusion from our study.
Moreover, it would be interesting to have a table comparing the baseline prognostic features of the two groups being compared.
Response: Thank you for the suggestion. We have now summarized and compared baseline characteristics between the two TTP groups (≥ 6 months) and (< 6 months) in Table 1 .
Another important point is that the question posed above by the authors could only be answered if a comparison was made with patients randomized to some other intervention than the trial therapy, because "an improvement in TTP" implies that using dabrafenib alone and combined with trametinib is better than using something else, as it would not make sense to talk about "improvement" by comparing patients similarly treated as in this trial (given that an improvement thus defined would only be in indication of the selection of the "best", responding patients).
Response: We agree that the research question would best be answered using data from a randomized trial. However, no randomized trial has been done in this population. As this information is not available, the analysis was done using data from the Phase II trial, the best information available to date. If a randomized trial were conducted in the future, we would propose to conduct the same analyses using the randomized trial data.
The use of Cox models per se is not an adequate means to eliminate the risk of guarantee-time bias; incidentally, the number of covariates used in the Cox models appears excessive vis-à-vis the number of events available for analysis. Please note the word "randomized" should be deleted from Figure 1 .
Response: Thank you for your comments on the Cox model approach. The potential issue of guarantee-time bias has been explored with the landmark analyses. This Cox approach was used to quantify the association between TTP and PPS, and was conducted with univariate and multivariate models. In the Cox model, we included all patient characteristics that can potentially confound the TTP-PPS association based on the data availability and clinical inputs. In addition, we have checked the validity of all Cox models presented in the manuscript to ensure that all models converge. Thank you for the comment on Figure 1 . The word "randomized" has been removed.
Reviewer 2 Reviewer Name: Hisao Imai Institution and Country: Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Japan Please state any competing interests or state 'None declared': None declared
This article is well written. Post progression survival is important for lung cancer patients to control overall survival. Patients haboring BRAF V600E mutation is also important for PPS. This article suggests the importance of PPS for those patients.
Response: Thank you for your comments on the manuscript.
Reviewer 3 Reviewer Name: Kari Chansky Institution and Country: Cancer Research And Biostatistics, USA Please state any competing interests or state 'None declared': None declared
The presentation must include a tabulation of the patient characteristics within each comparison group (TTP<6mos vs >=6 months). Currently the tabulation is shown by treatment cohort, which is interesting but not helpful in evaluating the results of the analysis. It is impossible to evaluate the correctness of the conclusions without knowing whether there are imbalances. A very likely imbalance in the number of prior treatment regimens is particularly concerning.
Response: Thank you for your thoughtful comments on the research question and suggestions on the approach. We have now summarized and compared baseline characteristics between the two TTP groups (≥ 6 months) and (<6 months) in Table 1 .
Multivariable analysis is helpful but does not completely eliminate doubts around imbalances, and the Kaplan Meier analyses are not adjusted for potential imbalances in these characteristics.
Response: Thank you for the comment. As you noted, Kaplan Meier curves present unadjusted comparison between the two survival curves and are the most commonly used approached for presenting time-to-event outcomes. For the Cox model, we agree that the current models may not completely eliminate imbalances in patient characteristics between the study groups. However, we have included all characteristics that may potentially confound the TTP-PPS association based on data availability and clinical inputs. Therefore, we think that the multivariable Cox model is an appropriate approach to address the research question and quantify TTP-PPS association in our study.
Response: Thank you; we have updated the section in the attached updated version of the manuscript.
Please modify your Data Sharing Statement to include full details of permissions to access the data used in your study, including whether the data was provided already anonymized.
Response: Thank you; we have updated the Data Sharing Statement in the attached updated version of the manuscript.
FORMATTING AMENDMENTS (if any)
Required amendments will be listed here; please include these changes in your revised version: 
GENERAL COMMENTS
I appreciate the authors' efforts to address the potential presence of guarantee-time bias. I only have two minor remaining concerns. The first pertains to the shape of Kaplan-Meier curves in the landmark analyses. Can authors clarify if they "reset the clock" to time zero purposefully? A typical K-M curve using a landmark shows a plateau at 100% in events between time zero and the landmark, but this usual feature is absent from the current figures. A second concern pertains to the uneven distribution of performance status between patients with or without progression at 6 months. Why do authors report the percentage of patients with PS > 1 before or at progression? Wouldn't it be better to have true baseline data? Could authors provide at least one sentence in the Discussion about this important difference, which could somehow affet the association between TTP and PPS?
VERSION 2 -AUTHOR RESPONSE
Reviewer Name: Everardo D. Saad Institution and Country: International Drug Development Institute (IDDI), Belgium I appreciate the authors' efforts to address the potential presence of guarantee-time bias. I only have two minor remaining concerns. The first pertains to the shape of Kaplan-Meier curves in the landmark analyses. Can authors clarify if they "reset the clock" to time zero purposefully? A typical K-M curve using a landmark shows a plateau at 100% in events between time zero and the landmark, but this usual feature is absent from the current figures. A second concern pertains to the uneven distribution of performance status between patients with or without progression at 6 months. Why do authors report the percentage of patients with PS > 1 before or at progression? Wouldn't it be better to have true baseline data? Could authors provide at least one sentence in the Discussion about this important difference, which could somehow affect the association between TTP and PPS?
Response: Thank you for the thorough review and comments. We agree that it makes sense to have the plateau. We reassessed the data and updated the Kaplan-Meier curves in the landmark analysis (Supplementary Figure 2) . In addition, we further clarified the choice of 3 months as the landmark in the methods section, in consideration that the median PPS was 2.7 months among all patients.
Regarding the second comment, we reported the ECOG score before or at progression rather than at trial baseline as it is closest to progression and more accurately reflected the disease status at the time of disease progression. It was also included and found to have a significant impact on the TTP-PPS association in the multivariable Cox model of PPS. In addition, we would like to understand whether controlling for baseline ECOG score would affect the estimated TTP-PPS association. So we conducted an exploratory analysis by adjusting for the ECOG score at baseline (while keeping all other covariates the same) using the multivariable Cox model. In the combined cohort, this exploratory analysis provided a similar result as that from the primary analysis. Each three-month increase in TTP was associated with a 39% reduction in the risk of post-progression death (HR 
